The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: Rationale and latest evidence

Therapeutic Advances in Medical Oncology

Volumn 4, Issue 2, 2012, Pages 61-73

  Lemech, Charlotte ^a   Infante, Jeffrey ^b   Arkenau, Hendrik Tobias ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

BRAF inhibitor; BRAF V600E; cutaneous melanoma; ipilimumab; MEK inhibitor; resistance; vemurafenib

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; B RAF KINASE; B RAF KINASE INHIBITOR; CARBOPLATIN; CHIR 265; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; DABRAFENIB; DACARBAZINE; DOCETAXEL; GSK 436; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SELUMETINIB; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; TRAMETINIB; UNCLASSIFIED DRUG; UO 126; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VEMURAFENIB;

ACNE; ADVANCED CANCER; ARTHRALGIA; BRAIN METASTASIS; CANCER SURVIVAL; CENTRAL SEROUS RETINOPATHY; COPY NUMBER VARIATION; CUTANEOUS MELANOMA; DIARRHEA; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; EXON; FATIGUE; HEART LEFT VENTRICLE FAILURE; HUMAN; KERATOACANTHOMA; MELANOMA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETINA VEIN OCCLUSION; RETINA VEIN THROMBOSIS; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SOMATIC MUTATION; THROMBOSIS; VOMITING;

EID: 84864464474     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834011432949     Document Type: Article

References (73)

1. Adjei A.A. Cohen R.B. Franklin W. Morris C. Wilson D. Molina J.R. et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD 6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26: 2139–2146.
2. Arkenau H.-T. Kefford R. Long G.V. (2010) Targeting BRAF for patients with melanoma. Br J Cancer 104: 392–398.
3. Balch C.M. Soong S.J. Gershenwald J.E. Thompson J.F. Reintgen D.S. Cascinelli N. et al. (2001) Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622–3634.
4. Bloom K.J. Anderson S.M. Schilling R.C. Lee J.R. Halait H. Cheng S. et al. (2011) Molecular testing for BRAF V 600 mutations in the BRIM-2 trial of the BRAF inhibitor vemurafenib in metastatic melanoma. J Clin Oncol 29(Suppl.): abstract 10523.
5. Boni A. Cogdill A.P. Dang P. Udayakumar D. Njauw C.N. Sloss C.M. et al. (2010) Selective BRAF V600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70: 5213–5219.
6. Calipel A. Lefevre G. Pouponnot C. Mouriaux F. Eychene A. Mascarelli F. (2003) Mutation in B-raf in human choroidal melanoma cell lines mediates cell proliferation and transformation through the MEK / ERK pathway. J Biol Chem 278: 42409–42418.
7. Cancer Research UK (2010) Skin Cancer – UK Incidence Statistics. Available at: http://info.cancerresearchuk.org/cancerstats/types/skin/incidence/ (accessed 29 November 2011).
8. Carlino M.S. Saunders C.A. Gebski V. Menzies A.M. Ma B. Lebowitz P.F. et al (2011) Heterogeneity of FDG-PET response to GSK2118436, an inhibitor of oncogenic mutant BRAF-kinase in BRAF-mutant metastatic melanoma. J Clin Oncol 29(Suppl.): abstract 10523.
9. Chapman P.B. Einhorh L.H. Meyers M.L. Saxman S. Destro A.N. Panageas K.S. et al. (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17: 2745–2751.
10. Chapman P.B. Hauschild A. Robert C. Haanen J.B. Ascierto P. Larkin J. et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 364: 2507–2516.
11. Cheng S. Chu P. Hinshaw M. Smith K. Maize J. Sferruzza A. (2011) Frequency of mutations associated with targeted therapy in malignant melanoma patients. J Clin Oncol 29(Suppl.): abstract 10523.
12. Chernoff K.A. Bordone L. Horst B. Simon K. Twadell W. Lee K. et al. (2009) GAB 2 amplifications refine molecular classification of melanoma. Clin Cancer Res 15: 4288–4291.
13. ClinicalTrials.gov (2011) www.clinicaltrials.gov (ClinicalTrials.gov Identifier NCT01227889, ClinicalTrials.gov Identifier NCT00936221, ClinicalTrials.gov Identifier NCT01256359, ClinicalTrials.gov Identifier NCT01166126 accessed 29 November 2011).
14. Corcoran R.B. Dias-Santagata D. Bergethon K. Iafrate J. Settleman J. Engelman J.A. (2010) BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harbouring the BRAF V600E mutation. Sci Signal 3: ra84.
15. Corcoran R.B. Settleman J. Engelman J.A. (2011) Potential therapetuic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2: 336–346.
16. Curtin J.A. Busam K. Pinkel D. Bastian B.C. (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340–4346.
17. Curtin J.A. Fridlyand J. Kageshita T. Patel H.N. Busam K.J. Kutzner H. et al. (2005) Distinct sets of genetic alterations in melanoma. New Engl J Med 353: 2135–2147.
18. Davies H. Bignell G.R. Cox C. Stephens P. Edkins S. Clegg S. et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949–954.
19. Dhomen N. Marais R. (2009) BRAF signalling and targeted therapies in melanoma. Hematol Oncol Clin North Am 23: 529–545.
20. Dummer R. Robert C. Chapman P.B. Sosman J.A. Middleton M. Bastholt L. et al. (2008) AZD 6244 (ARRY-142886) vs temozolomide (TMZ) in patients with advanced melanoma: an open-label, randomized, multicenter, phase II study. J Clin Oncol 26(Suppl.): abstract 10523.
21. Edlundh-Rose E. Egyhazi S. Omholt K. Mansson-Brahme E. Platz A. Hansson J. et al. (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16: 471–478.
22. Eigentler T.K. Caroli U.M. Radny P. Garbe C. (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomized clinical trials. Lancet Oncol 4: 748–759.
23. Eisen T. Ahmad T. Flaherty K.T. Gore M. Kaye S. Marais R. et al. (2006) Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 95: 581–586.
24. Emery C.M. Vijayendram K.G. Zipser M.C. Sawyer A.M. Niu L. Kim J.J. et al. (2009) MEK 1 mutations confer resistance to MEK and BRAF inhibition. Proc Natl Acad Sci U S A 106: 20411–20416.
25. Falchook G. Infante J.R. Fecher L.A. Gordon M.S. Vogelzang N.J. de Marini D.J. et al. (2010) The oral MEK 1 / 2 inhibitor GSK 1120212 demonstrates early efficacy signals. Ann Oncol 21(Suppl. 8): abstract 10523.
26. Flaherty K.T. (2011) Is it good or bad to find a BRAF mutation? J Clin Oncol 29: 1229–1230.
27. Flaherty K.T. Puzanov I. Kim K.B. Ribas A. McArthur G.A. Sosman J.A. et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. New Engl J Med 363: 809–819.
28. Gopal Y.N.V. Deng W. Woodman S.E. Komurov K. Ram P. Smith P.D. et al. (2010) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD 6244 (ARRY-142886) in Braf-mutant cutaneous melanoma cells. Cancer Res 70: 8736–8747.
29. Hauschild A. Agarwala S.S. Trefzer U. Hogg D. Robert C. Hersey P. et al. (2009) Results of a phase III, randomized placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or IV melanoma. J Clin Oncol 27: 2823–2830.
30. Hodi F.S. O'Day S.J. McDermott D.F. Weber R.W. Sosman J.A. Haanen J.B. et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 363: 711–723.
31. Hoeflich K.P. Gray D.C. Eby M.T. Tien J.Y. Wong L. Bower J. et al. (2006) Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 66: 999–1006.
32. Houben R. Becker J.C. Kappel A. Terheyden P. Brocker E. Goetz R. et al. (2004) Constitutive activation of the Ras-Raf signalling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3: 6.
33. Infante J. Falchook G. Lawrence D. Weber J.S. Kefford R.F. Bendell J.C. et al. (2011) Phase I / II study to assess safety, pharmacokinetics, and efficacy of the oral MEK1/2 inhibitor GSK 1120212 dosed in combination with the oral BRAF inhibitor GSK2118436. J Clin Oncol 29(Suppl.): abstract CRA8503.
34. Infante J.R. Fecher L.A. Nallapareddy S. Gordon M.S. Flaherty K.T. Cox D.S. et al. (2010) Safety and efficacy results from the first-in-human study of the oral MEK 1 / 2 inhibitor GSK1120212. J Clin Oncol 28(Suppl.): abstract 2503.
35. Jakob J.A. Bassett R.L. Ng C.S. Lazar A.J.F. Alvarado G.C. Rohlfs M.L. et al. (2011) Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. J Clin Oncol 29(Suppl.): abstract 10523.
36. Jiang C.C. Lai F. Thorne R.F. Yang F. Liu H. Hersey P. Zhang X.D. (2011) MEK-independent survival of B-RAF V600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 17: 721–730.
37. Johannessen C.M. Boehm J.S. Kim S.Y. Thomas S.R. Wardwell L. Johnson L.A. et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968–972.
38. Karasarides M. Chiloeches A. Hayward R. Niculescu-Duvaz D. Scanlon I. Friedlos F. et al. (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23: 6292–6298.
39. Kefford R. (2010) Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010. Pigment Cell Mel Res 24: e1–e15.
40. Kefford R. Arkenau H. Brown M.P. Millward M. Infante J.R. Long G.V. et al. (2010) Phase I / II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumours. J Clin Oncol 28(Suppl.): abstract 10523.
41. Little A.S. Balmanno K. Sale M.J. Newman S. Dry J.R. Hampson M. et al. (2011) Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal 4: ra17.
42. Liu W. Kelly J.W. Trivett M. Murray W.K. Dowling J.P. Wolfe R. et al. (2006) Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 127: 900–905.
43. Long G.V. Menzies A.M. Nagrial A.M. Haydu L.E. Hamilton A.L. Mann G.J. et al. (2011 a) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29: 1239–1246.
44. Long G.V. Wilmott J.S. Howle J.R. Chatfield M.D. Tembe V. Thompson J.F. et al. (2011 b) Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients on BRAF inhibitors (BRAFi). J Clin Oncol 29(Suppl.): abstract 10523.
45. Long G.V. Kefford R.F. Carr P.J.A. Brown M.P. Curtis M. Ma B. et al. (2010) Phase 1 / 2 study of GSK2118436, a selective inhibitor of V 600 mutant (Mut) BRAF kinase: evidence of activity in melanoma brain metastases (Mets). Ann Oncol 21(Suppl. 8): abstract LBA27.
46. Lorusso P.M. Krishnamurthy S. Rinehart J. Nabell L. Croghan G. Varterasian M. et al. (2005) A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901, in patients with advanced cancer. J Clin Oncol 23: 3011.
47. McArthur G.A. Puzanov I. Ribas A. Chapman P.B. Kim K.B. Sosman J.A. et al. (2010) Early FDG-PET responses to PLX 4032 in BRAF-mutant advanced melanoma. J Clin Oncol 28(Suppl.): abstract 10523.
48. McArthur G. Ribas A. Chapman P.B. Flaherty K.T. Kim K.B. Puzanov I. et al. (2011) Molecular analyses from a phase 1 trial of vemurafenib to study mechanism of action and resistance in repeated biopsies from BRAF mutation positive metastatic melanoma patients. J Clin Oncol 29(Suppl.): abstract 10523.
49. McDermott D.F. Sosman J.A. Gonzalez R. Hodi F.S. Linette G.P. Richards J. et al. (2008) Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 26: 2178–2185.
50. Menzies A.M. Visintin L. Chatfield M.D. Carlino M.S. Howle J.R. Scolyer R.A. et al. (2011) BRAF mutation by age-decade and body mass index in metastatic melanoma. J Clin Oncol 29(Suppl.): abstract 10523.
51. Messersmith W.A. Hidalgo M. Carducci M. Eckhardt S.G. (2006) Novel targets in solid tumors: MEK inhibitors. Clin Adv Hematol Oncol 4: 831–836.
52. Middleton M.R. Grob J.J. Aaronson N. Fierlbeck G. Tilgen W. Seiter S. et al. (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18: 158–166.
53. Montagut C. Sharma S.V. Shioda T. McDermott U. Ulman M. Ulkus L.E. et al. (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68: 4853–4861.
54. Nathanson K.L. Martin A. Letrero R. D'Andrea K.P. O'Day S. Infante J.R. et al. (2011) Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK 2118436 (GSK436). J Clin Oncol 29(Suppl.): abstract 10523.
55. National Cancer Institute (2010) A Snapshot of Melanoma. Available at: www.cancer.gov/aboutnci/servingpeople/snapshots/melanoma.pdf (accessed 29 November 2011).
56. National Cancer Institute – Surveillance Epidemiology and End Results (2010) SEER Stat Fact Sheets: Melanoma of the Skin. Available at: http://seer.cancer.gov/statfacts/html/melan.html (accessed 29 November 2011).
57. Nazarian R. Shi H. Wang Q. Kong X. Koya R.C. Lee H. et al. (2010) Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973–977.
58. Paraiso K.H.T. Xiang Y. Rebecca V.W. Abel E.V. Chen Y.A. Munko A.C. et al. (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71: 2750–2760.
59. Platz A. Egyhazi S. Ringborg U. Hansson J. (2008) Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenic subclass and body site. Mol Oncol 1: 395–405.
60. Ribas A. Kim K.B. Schuchter L.M. Gonzalez R. Pavlick A.C. Weber J.S. et al. (2011) BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600E mutation-positive melanoma. J Clin Oncol 29(Suppl.): 8509.
61. Robert C. Thomas L. Bondarendo I. O'Day S. Garbe C. Lebbe C. et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 364: 2517–2526.
62. Rubinstein J.C. Sznol M. Pavlick A.C. Ariyah S. Cheng E. Bacchiocchi A. et al. (2010) Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 6: 67.
63. Sauter E.R. Yeo U.C. von Stemm A. Zhu W. Litwin S. Tichansky D.S. et al. (2002) Cyclin D 1 is a candidate oncogene in cutaneous melanoma. Cancer Res 62: 3200–3206.
64. Shao Y. Aplin A.E. (2010) Akt3-mediated resistance to apoptosis in BRAF-targeted melanoma cells. Cancer Res 70: 6670–6681.
65. Smalley K.S.M. Contractor R. Nguyen T.K. Xiao M. Edwards R. Muthusamy V. et al. (2008 b) Identification of a novel sub-group of melanomas with KIT / cyclin dependent kinase-4 overexpression. Cancer Res 68 (14): 5743–5752.
66. Smalley K.S.M. Lioni M. Palma M.D. Xiao M. Desai B. Egyhazi S. et al. (2008 a) Increased cyclin D 1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanoma. Mol Cancer Ther 7: 2876–2883.
67. Thomas N.E. Edmiston S.N. Alexander A. Millikan R.C. Groben P.A. Hao H. et al. (2007) Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer. Epidemiol Biomarkers Prev 16: 991–997.
68. Villanueva J. Vultur A. Lee J.T. Somasundaram R. Fukunaga-Kalabis M. Cipolla A.K. et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by targeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683–695.
69. Viros A. Fridlyand J. Bauer J. Lasithiotakis K. Garbe C. Pinkel D. et al. (2008) Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 5: e120.
70. Wagle N. Emery C. Berger M.F. Davis M.J. Sawyer A. Pochanard P. et al. (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29: 3085–3096.
71. Wellcome Trust Sanger Institute (2011) Cosmic database, www.sanger.ac.uk/cosmic/ (accessed 29 November 2011).
72. Whittaker S. Kirk R. Hayward R. Zambon A. Viros A. Cantarino N. et al. (2010) Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med 2: 35–41.
73. Zhang X.D. Borrow J.M. Zhang X.Y. Nguyen T. Hersey P. (2003) Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac / DIABLO release from mitochondria. Oncogene 22: 2869–2881.